title: Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors.
abstract: Predictors of virologic (plasma HIV RNA viral load [VL] < 500 copies/ml) and immunologic (rise in CD4+ cell count > 50 cells/mm3) response after 4 months of therapy (M4) were studied in 750 HIV-1-infected patients prospectively enrolled at the initiation of a protease inhibitor (PI)-containing regimen. A virologic response was observed in 80% of patients, and an immunologic response was observed in 64%. Sixty-two percent of patients self-reported full adherence to therapy at 1 month of therapy (M1) and M4. In multivariate analysis, a virologic response was more frequent in fully adherent patients (odds ratio [OR] = 2.0; p =.001). An immunologic response was associated with age < 36 years (OR =1.4; p =.03), baseline VL (OR = 1.5 per 1 log10 copies/ml higher; p <.01), decrease in VL at M1 (OR = 1.5 per 1 log10 copies/ml decrease; p <.01), baseline total lymphocyte count (OR = 1.7 per 50% lower; p <.001), and baseline CD4+ cell percentage > or = 20% (OR =1.9; p <.001) but not with adherence to therapy. Full adherence seems to be a major predictor of a virologic response to PI-containing triple therapy. An immunologic response may be possible despite incomplete adherence, at least early in therapy.
authors.affiliation: Hôpital Bichat-Claude Bernard, Paris; INSERM U 330, Bordeaux; INSERM U 379, Marseille, France.
authors.forename: V
authors.initials: V
authors.lastname: Le Moing
authors.forename: G
authors.initials: G
authors.lastname: Chêne
authors.forename: M P
authors.initials: MP
authors.lastname: Carrieri
authors.forename: J M
authors.initials: JM
authors.lastname: Besnier
authors.forename: B
authors.initials: B
authors.lastname: Masquelier
authors.forename: R
authors.initials: R
authors.lastname: Salamon
authors.forename: C
authors.initials: C
authors.lastname: Bazin
authors.forename: J P
authors.initials: JP
authors.lastname: Moatti
authors.forename: F
authors.initials: F
authors.lastname: Raffi
authors.forename: C
authors.initials: C
authors.lastname: Leport
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005602:France; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D015999:Multivariate Analysis; D010349:Patient Compliance; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral